CytoDyn Inc CYDY

Healthcare Biotechnology

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.

OTCQB:CYDY - Post by User

CytoDyn Inc

Bullboard Posts

Post by sunny3999on May 11, 2020 3:50pm

72 Views

Post# 31013645

Shorts getting hammered in Pharma sektor!

Shorts will be tarred, feathered and chased out of Cytodyn

“We will probably see short covering in stocks with over -50% returns over the last month as short-sellers trim their exposure in order to cut their losses,” Dusaniwsky said.

Bullboard Posts

Rich TV Live’s Stocks to Watch this week (Nov. 15, 2024)